Tianhui Chen

Prof. Tianhui Chen

Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences (CAS), Hangzhou, China
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
XJXiyi Jiang
Xiyi Jiang
HTHuijuan Tang
Huijuan Tang
Tianhui ChenTianhui Chen
Tianhui Chen
Jiang X, et al. J Gynecol Oncol. 2017 Sep;29(1):e7. https://doi.org/10.3802/jgo.2018.29.e7

6 February 2023 in eClinicalMedicine
Verified
Journal Article
Open access
LYLi Yuan
Li Yuan
LYLin Yang
Lin Yang
SZShichuan Zhang
Shichuan Zhang
ZXZhiyuan Xu
Zhiyuan Xu
JQJiangjiang Qin
Jiangjiang Qin
XCXiangdong Cheng
Xiangdong Cheng
Tongue images (the colour, size and shape of the tongue and the colour, thickness and moisture content of the tongue coating), reflecting the health state of the whole body according to the theory of traditional Chinese medicine (TCM), have been widely used in China for thousands of years. Herein, we investigated the value of tongue images and the tongue coating microbiome in the diagnosis of gastric cancer (GC). From May 2020 to January 2021, we simultaneously collected tongue images and tongue coating samples from 328 patients with GC (all newly diagnosed with GC) and 304 non-gastric cancer (NGC) participants in China, and 16 S rDNA was used to characterize the microbiome of the tongue coating samples. Then, artificial intelligence (AI) deep learning models were established to evaluate the value of tongue images and the tongue coating microbiome in the diagnosis of GC. Considering that tongue imaging is more convenient and economical as a diagnostic tool, we further conducted a prospective multicentre clinical study from May 2020 to March 2022 in China and recruited 937 patients with GC and 1911 participants with NGC from 10 centres across China to further evaluate the role of tongue images in the diagnosis of GC. Moreover, we verified this approach in another independent external validation cohort that included 294 patients with GC and 521 participants with NGC from 7 centres. This study is registered at ClinicalTrials.gov, NCT01090362. For the first time, we found that both tongue images and the tongue coating microbiome can be used as tools for the diagnosis of GC, and the area under the curve (AUC) value of the tongue image-based diagnostic model was 0.89. The AUC values of the tongue coating microbiome-based model reached 0.94 using genus data and 0.95 using species data. The results of the prospective multicentre clinical study showed that the AUC values of the three tongue image-based models for GCs reached 0.88-0.92 in the internal verification and 0.83-0.88 in the independent external verification, which were significantly superior to the combination of eight blood biomarkers. Our results suggest that tongue images can be used as a stable method for GC diagnosis and are significantly superior to conventional blood biomarkers. The three kinds of tongue image-based AI deep learning diagnostic models that we developed can be used to adequately distinguish patients with GC from participants with NGC, even early GC and precancerous lesions, such as atrophic gastritis (AG). The National Key R&D Program of China (2021YFA0910100), Program of Zhejiang Provincial TCM Sci-tech Plan (2018ZY006), Medical Science and Technology Project of Zhejiang Province (2022KY114, WKJ-ZJ-2104), Zhejiang Provincial Research Center for Upper Gastrointestinal Tract Cancer (JBZX-202006), Natural Science Foundation of Zhejiang Province (HDMY22H160008), Science and Technology Projects of Zhejiang Province (2019C03049), National Natural Science Foundation of China (82074245, 81973634, 82204828), and Chinese Postdoctoral Science Foundation (2022M713203).

1 January 2016 in Cancer Letters
Verified
Journal Article
Closed access
RZRongshou Zheng
Rongshou Zheng
HZHongmei Zeng
Hongmei Zeng
SZSiwei Zhang
Siwei Zhang
Tianhui ChenTianhui Chen
Tianhui Chen
WCWanqing Chen
Wanqing Chen

1 November 2011 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
ATAdetunji Toriola
Adetunji Toriola
MVMarja Vääräsmäki
Marja Vääräsmäki
MLMatti Lehtinen
Matti Lehtinen
AZAnne Zeleniuch-Jacquotte
Anne Zeleniuch-Jacquotte
ELEva Lundin
Eva Lundin
ALAnnekatrin Lukanova
Annekatrin Lukanova
OBJECTIVE: To examine the associations of maternal and child characteristics with early pregnancy maternal concentrations of testosterone, androstenedione, progesterone, 17-hydroxyprogesterone, and estradiol (E2). METHODS: We analyzed these hormones among 1,343 women with singleton pregnancies who donated serum samples to the Finnish Maternity Cohort from 1986 to 2006 during the first half of pregnancy (median 11 weeks). The associations of maternal and child characteristics with hormone concentrations were investigated by correlation and multivariable regression. RESULTS: Women older than age 30 years had lower androgen and E2 but higher progesterone concentrations than women younger than that age. Multiparous women had 14% lower testosterone, 11% lower androstenedione and 17-hydroxyprogesterone, 9% lower progesterone, and 16% lower E2 concentrations compared with nulliparous women (all P<.05). Smoking mothers had 11%, 18%, and 8% higher testosterone, androstenedione, and 17-hydroxyprogesterone levels, respectively, but 10% lower progesterone compared with nonsmoking women (all P<.05). E2 concentrations were 9% higher (P<.05) among women with a female fetus compared with those with a male fetus. CONCLUSION: Parity, smoking, and, to a lesser extent, maternal age and child sex are associated with sex steroid levels during the first half of a singleton pregnancy. The effects of smoking on the maternal hormonal environment and the possible long-term deleterious consequences on the fetus deserve further evaluation. LEVEL OF EVIDENCE: II

18 February 2019 in Genome Medicine
Verified
Journal Article
Open access
PDF file
RSRaunak Shrestha
Raunak Shrestha
NNNoushin Nabavi
Noushin Nabavi
YLYen-Yi Lin
Yen-Yi Lin
FMFan Mo
Fan Mo
SAShawn Anderson
Shawn Anderson
CCColin Collins
Colin Collins
Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted therapies for PeM exist. Some immune checkpoint inhibitor studies of mesothelioma have found positivity to be associated with a worse prognosis. To search for novel therapeutic targets for PeM, we performed a comprehensive integrative multi-omics analysis of the genome, transcriptome, and proteome of 19 treatment-naïve PeM, and in particular, we examined BAP1 mutation and copy number status and its relationship to immune checkpoint inhibitor activation. We found that PeM could be divided into tumors with an inflammatory tumor microenvironment and those without and that this distinction correlated with haploinsufficiency of BAP1. To further investigate the role of BAP1, we used our recently developed cancer driver gene prioritization algorithm, HIT’nDRIVE, and observed that PeM with BAP1 haploinsufficiency form a distinct molecular subtype characterized by distinct gene expression patterns of chromatin remodeling, DNA repair pathways, and immune checkpoint receptor activation. We demonstrate that this subtype is correlated with an inflammatory tumor microenvironment and thus is a candidate for immune checkpoint blockade therapies. Our findings reveal BAP1 to be a potential, easily trackable prognostic and predictive biomarker for PeM immunotherapy that refines PeM disease classification. BAP1 stratification may improve drug response rates in ongoing phases I and II clinical trials exploring the use of immune checkpoint blockade therapies in PeM in which BAP1 status is not considered. This integrated molecular characterization provides a comprehensive foundation for improved management of a subset of PeM patients.

1 July 2015 in Cancer Letters
Verified
Journal Article
Closed access
RZRongshou Zheng
Rongshou Zheng
XPXiaoxia Peng
Xiaoxia Peng
HZHongmei Zeng
Hongmei Zeng
SZSiwei Zhang
Siwei Zhang
Tianhui ChenTianhui Chen
Tianhui Chen
WCWanqing Chen
Wanqing Chen